Making a difference in healthcare
Our world-leading researchers focus on the development and treatment of new avenues for the prevention, diagnosis and treatment of major public health problems that affect millions of people globally.
These medical problems include eye disease, diabetic complications, cardiovascular disease, antibiotic resistance and common lung illnesses such as asthma, COPD, cystic fibrosis and pneumonia.
Our inter-disciplinary research delivers innovative and translational science research, alongside insightful health services discoveries, leading to real-world impact in health and healthcare, beyond the lab.
OUR RESEARCH HUBS
Our research integrates the full translational and innovation spectrum, spanning from fundamental discovery science, leveraging molecular/cellular/human models, to co-design and evaluation of health and healthcare solutions with end-users and developing innovative solutions and therapeutics to benefit industry and healthcare.
Our Research is funded by UKRI, NIHR, UK charities and many EU funders. Our Research partnerships with UKRI, NIHR, Wellcome Trust and other high-quality funding.
Our Research partnerships with Industry and Health and Social Care Trusts have led to increased translation of research into practice and 9 spin out companies.
Involving patients as part of our research has ensured our work is grounded in the reality of clinical conditions and their debilitating effects on individuals. We have pioneered the interaction with patient groups as an integral part of our research, such as in our Cancer Caring Coping initiative, an online intervention to support carers which is integrated into the health services of all five healthcare trusts in Northern Ireland.
The University, in conjunction with China Medical University in Shenyang, China, has established the China Medical University–Queen’s University Belfast Joint College (CQC) which provides undergraduate programmes in Pharmaceutical Sciences and Pharmaceutical Biotechnology, degrees developed by the School of Pharmacy.
A further educational collaboration with the Mohammed bin Rashid University of Medicine in Dubai is now leading to promising research links in data science, child health and infectious diseases, and Queen’s hosts PhD students from the University.
Through CESI we further our interdisciplinary research to produce robust research evidence to help improve the lives of children, families and communities.
Through MATCH we collaborate with colleagues from Schools of Pharmacy, Chemistry and Chemical Engineering, Mechanical and Aerospace Engineering and others to address the global need for smarter materials and advanced technologies to improve health outcomes in an orthopaedic setting.
Our staff work collaboratively with healthcare partners to change public health practice, such as in directly leading key screening services, engaging with and acting as key advisors to government departments and working with local public health agencies to co-produce and design research trials, as well as helping to shape the agendas of global health organisations such as the WHO.
We have strong relationships with the NHS and industry in which we share knowledge and facilities, helping us turn our discoveries into effective new therapies.
Our researchers work is designed to ensure maximum impact on policy, on society and on patient outcomes:
- Use of linked data from the Agricultural Census and the main Population Census, to gain a better understanding of the health, welfare and educational issues affecting farming communities in NI
- Demonstrated the potential impact on public health of community greenway development
There is a vibrant and highly supportive research culture across the University.
Our dedicated Postdoctoral Development Centre supports training and development of all post-doctoral fellows. We have an expanding group of postdoctoral researchers from a variety of applied health discipline backgrounds who contribute to a diversity of multidisciplinary research.
The Queen’s Fellowship Academy provides professional and career development for research fellows in the early-stage of their careers with research interests that align with current research strengths at Queen’s.
Our Graduate School is a vibrant hub for intellectual development, exchange and collaboration, supporting postgraduates to be thinkers, communicators, innovators and leaders who are future ready.
We invest millions in the development of our research facilities to ensure that our staff, students and collaborators have the very best equipment to help them in their work.
Through the new state-of-the-art KN Cheung SK Chin InterSim Centre, we will deliver world class interdisciplinary simulation based clinical education and professional development activities to hundreds of students each year. It will bring the challenging realities of modern day clinical practice to life such as acute and emergency care, chronic illness, paediatrics, mental health and maternity services, and simulate a range of environments from a hospital ward, to a resuscitation suite, outpatient department, and importantly, a patient’s home environment.
Our £32M Wellcome-Wolfson Institute for Experimental Medicine is a state-of-the-art research facility containing a large suite of open-plan multipurpose research laboratories including numerous tissue culture, molecular biology, biochemistry and microbiology laboratories.
Our success in Athena SWAN awards including a new Gold award and renewal of two Silver Awards, recognises our commitment to addressing gender equality, representation, progression and success for all our staff.
LOOKING TO THE FUTURE
Queen’s is a key partner in the Belfast Region City Deal, a £1 billion investment, bringing regional government, industry and universities together to develop Northern Ireland’s economy and society. Included within this investment are the Research Innovation projects including the Global Innovation Institute (GII; data security, informatics, analytics), the Institute for Research Excellence in Advanced Clinical Healthcare (iREACH) and the Advanced Manufacturing Innovation Centre (AMIC), all of which will present significant opportunities.
We are co-leading a global research programme devoted to vision and the Sustainable Development Goals.
Queen’s has long been committed to enriching society both locally and globally, and has been involved in proactively and holistically addressing the global challenges we face.
Poor vision, the world’s largest unmet disability, affects 2.2 billion people. We are co-leading a Research programme, 'ENGINE', which will examine how an affordable, effective and widely available treatment, glasses, can help achieve the United Nation’s Sustainable Development Goals across the life course.
We aim to drive lasting policy change, achieve improved quality of life for people in low and middle-income countries, and help achieve the SDGs across the world.
Professor Kee is the Director of the Centre for Public Health in the School of Medicine, Dentistry and Biomedical Sciences, and previously directed one of the UKCRC Centres of Excellence for Public Health Research (2008-2018).
An internationally renowned scientist with over 30 years experience in cancer research, who is passionate about translating his research for the benefit of patients and society.
Professor Fitzsimons' research is focused on improving care for people with chronic conditions, particularly in helping them better understand their illness, engage in effective self-management, embrace preventative strategies and achieve optimal end of life care.
Professor Reid uses mixed methodologies to focus on cancer care and palliative care for both malignant and non-malignant conditions. Her predominate area of research focuses on cachexia.
Prof McCarthy’s research team have focused on the development of non-viral delivery systems for nanomedicine applications in the School of Pharmacy.
Dr. Laverty's Biofunctional Nanomaterials group research the development of unique materials for biomedical applications based on the building blocks of life (e.g. peptides).
Investigating the potential contribution of inter-track interactions within ultra-high dose-rate proton therapy2 February 2023
Establishing healthy eating ‘habits’: a pilot randomised controlled trial of a habit-based dietary intervention following oral rehabilitation for older adults
- Sinead Watson
- Leigh-Ann McCrum
- Bernadette McGuinness
- Christopher Cardwell
- Mike Clarke
- Jayne Woodside
- Gerry McKenna
- Laura McGowan
- 1 February 2023
Outcomes reporting in systematic reviews on vital pulp treatment: A scoping review for the development of a core outcome set1 February 2023
- Gerard Walls
- Mihaela Ghita
- Rachel Queen
- Kevin Edgar
- Eleanor K. Gill
- Refik Kuburas
- David Grieve
- Chris Watson
- Alan McWilliam
- Marcel Van Herk
- Kaye J. Williams
- Aidan Cole
- Suneil Jain
- Karl Butterworth